APR Pharma SRL
APR Pharma reported total assets of 244,955 € at the end of the 2025 financial year (annual accounts filed with the NBB on 19 Aug 2026).
The score of APR Pharma shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +55 % Total assets -21 %
Accounts of the company itself (not consolidated).
The full file covers 5 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
APR Pharma's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | 39,279 € | ||||
| Equity | 93,506 € | ||||
| Cash | 46,448 € | ||||
| EBITDA | 69,997 € | ||||
| Total assets | 244,955 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 19 Aug 2026
- Year ended 31 Dec 2024filed on 15 Jul 2025
- Year ended 31 Dec 2023filed on 24 Jun 2024
- Year ended 31 Dec 2022filed on 26 Jun 2023
- Year ended 31 Dec 2021filed on 29 Aug 2022
APR Pharma's financial analysis
- Solvency38.2%sector median: 46.9%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of APR Pharma
APR Pharma's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0748.905.227
- VAT number
- BE0748905227
- Peppol
- Registered · 0208:0748905227 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 24 Jun 2020
- Registered office
- 6180 Courcelles
- Latest accounts
- 2025 · filed on 19 Aug 2026
- Activity
- Manufacture of basic pharmaceutical products (NACE 21100)
APR Pharma (SRL) has been based in Courcelles since 2020, active in: manufacture of basic pharmaceutical products. For 2025, it reports a net profit of 39,279 € and equity of 93,506 €; its revenue is not published. Its solvency stands at 38.2%, below the median of its sector (46.9%).
Companies similar to APR Pharma
Companies in the same business, of comparable size and area, outside its group.
- Novozymatic Manufacture of basic pharmaceutical products Kapellen · balance sheet 148,440 €
- Efrax Manufacture of pharmaceutical preparations Brasschaat · balance sheet 577,651 €
- NO Headache Manufacture of basic pharmaceutical products Uccle · balance sheet 261,728 €
- Vroome Pharma Management Retail sale of pharmaceutical products Antwerp · balance sheet 229,894 €
- QP Pro Services Manufacture of basic pharmaceutical products Gembloux · balance sheet 304,804 €
- Clinical Research Vanackere Manufacture of basic pharmaceutical products Tielt-Winge · balance sheet 263,927 €
- G²VH Impact Activities of holding companies Boutersem · balance sheet 128,601 €
- Pharmacie Baron DE Castro Retail sale of pharmaceutical products Etterbeek · balance sheet 285,240 €
Frequently asked questions about APR Pharma
What is the revenue of APR Pharma?
APR Pharma files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of APR Pharma?
In Belgium, the VAT number is the company number prefixed with BE: BE0748905227 for APR Pharma, if the company is VAT-registered. Its company number (CBE) is 0748.905.227.
Where is the registered office of APR Pharma?
According to the CBE register, the registered office of APR Pharma is in 6180 Courcelles.
What is the equity of APR Pharma?
At the close of the 2025 financial year, the equity of APR Pharma amounts to 93,506 €, a solvency of 38.2% of total assets.
Who manages APR Pharma?
The register lists 8 active mandates at APR Pharma. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of APR Pharma
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →